ORIC
Oric Pharmaceuticals Inc
NASDAQ · Biotechnology
$10.42
+0.46 (+4.62%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 151.33M | 156.80M | 123.33M |
| Net Income | -16,895,209 | -20,414,835 | -15,522,009 |
| EPS | — | — | — |
| Profit Margin | -11.2% | -13.0% | -12.6% |
| Rev Growth | +7.8% | +20.1% | +4.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 205.57M | 268.25M | 239.63M |
| Total Equity | 573.02M | 595.16M | 557.09M |
| D/E Ratio | 0.36 | 0.45 | 0.43 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -22,168,918 | -26,679,727 | -20,408,682 |
| Free Cash Flow | -10,591,679 | -9,966,569 | -9,555,180 |